Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 842

1.

Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.

Hoppe BS, Moskowitz CH, Filippa DA, Moskowitz CS, Kewalramani T, Zelenetz AD, Yahalom J.

J Clin Oncol. 2008 Apr 10;26(11):1858-64. doi: 10.1200/JCO.2007.15.4773. Epub 2008 Mar 10. Erratum in: J Clin Oncol. 2008 Aug 20;26(24):4053. Zelenet, Andrew D [corrected to Zelenetz, Andrew D].

PMID:
18332466
2.

Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study.

Czyzewski EA, Goldman S, Mundt AJ, Nachman J, Rubin C, Hallahan DE.

Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):569-77.

PMID:
10348286
3.

The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.

Hoppe BS, Moskowitz CH, Zhang Z, Maragulia JC, Rice RD, Reiner AS, Hamlin PA, Zelenetz AD, Yahalom J.

Bone Marrow Transplant. 2009 Jun;43(12):941-8. doi: 10.1038/bmt.2008.408. Epub 2009 Jan 12.

PMID:
19139730
4.

Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.

Dawson LA, Saito NG, Ratanatharathorn V, Uberti JP, Adams PT, Ayash LJ, Reynolds CM, Silver SM, Schipper MJ, Lichter AS, Eisbruch A.

Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):208-18.

PMID:
15093918
5.

High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.

Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM.

Biol Blood Marrow Transplant. 2005 Jan;11(1):13-22.

6.

Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.

Cairoli R, Grillo G, Tedeschi A, Gargantini L, Marenco P, Tresoldi E, Barbarano L, Nosari AM, Morra E.

Bone Marrow Transplant. 2002 Mar;29(6):473-7.

7.

Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.

Biswas T, Dhakal S, Chen R, Hyrien O, Bernstein S, Friedberg JW, Fisher RI, Liesveld J, Phillips G, Constine LS.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):79-85. doi: 10.1016/j.ijrobp.2009.04.036. Epub 2009 Aug 3.

PMID:
19647953
8.
9.

[Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].

Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX.

Ai Zheng. 2006 Dec;25(12):1543-9. Chinese.

PMID:
17166383
10.

Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies.

Vlachaki MT, Ha CS, Hagemeister FB, Fuller LM, Rodriguez MA, Besa PC, Hess MA, Brown B, Cabanillas F, Cox JD.

Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):609-16.

PMID:
9336140
11.
12.

Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.

Wilder RB, Tucker SL, Ha CS, Rodriguez MA, Hess MA, Cabanillas FF, Cox JD.

Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):17-22.

PMID:
11163493
13.

Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.

Kahn ST, Flowers CR, Lechowicz MJ, Hollenbach K, Johnstone PA.

Cancer J. 2005 Sep-Oct;11(5):425-31.

PMID:
16259874
14.

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, Louie D, Gonzales M, Walits J, Coady-Lyons N, Qin J, Frank R, Bertino JR, Goy A, Noy A, O'Brien JP, Straus D, Portlock CS, Yahalom J.

Blood. 2001 Feb 1;97(3):616-23.

15.

The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant.

Wendland MM, Smith DC, Boucher KM, Asch JD, Pulsipher MA, Thomson JW, Shrieve DC, Gaffney DK.

Am J Clin Oncol. 2007 Apr;30(2):156-62.

PMID:
17414465
17.

[High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].

Zhou SY, Shi YK, He XH, Han XH, Liu P, Yang JL, Zhou AP, Feng FY.

Ai Zheng. 2002 Apr;21(4):405-8. Chinese.

PMID:
12452021
18.

Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma.

Stemmer SM, Pfeffer MR, Rizel S, Hardan I, Goffman J, Gezin A, Neumann A, Kitsios P, Alezra D, Brenner HJ.

Cancer. 2001 Jun 1;91(11):1983-91.

PMID:
11391576
19.

The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum.

Nguyen LN, Ha CS, Hess M, Romaguera JE, Manning JT, Cabanillas F, Cox JD.

Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1281-5.

PMID:
10889382
20.

Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?

Kahn S, Flowers C, Xu Z, Esiashvili N.

Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):175-80. doi: 10.1016/j.ijrobp.2010.05.010. Epub 2010 Aug 21.

PMID:
20732769

Supplemental Content

Support Center